...
首页> 外文期刊>Archives of Toxicology >The pharmacokinetics and metabolism of diclofenac in chimeric humanized and murinized FRG mice
【24h】

The pharmacokinetics and metabolism of diclofenac in chimeric humanized and murinized FRG mice

机译:双氯芬酸的药代动力学和代谢在嵌合人源化和鼠芥子小鼠中的药代动力学和代谢

获取原文
获取原文并翻译 | 示例

摘要

The pharmacokinetics of diclofenac were investigated following single oral doses of 10 mg/kg to chimeric liver humanized and murinized FRG and C57BL/6 mice. In addition, the metabolism and excretion were investigated in chimeric liver humanized and murinized FRG mice. Diclofenac reached maximum blood concentrations of 2.43 +/- 0.9 mu g/mL (n = 3) at 0.25 h post-dose with an AUC(inf) of 3.67 mu g h/mL and an effective half-life of 0.86 h (n = 2). In the murinized animals, maximum blood concentrations were determined as 3.86 +/- 2.31 mu g/mL at 0.25 h post-dose with an AUC(inf) of 4.94 +/- 2.93 mu g h/mL and a half-life of 0.52 +/- 0.03 h (n = 3). In C57BL/6J mice, mean peak blood concentrations of 2.31 +/- 0.53 mu g/mL were seen 0.25 h post-dose with a mean AUC(inf) of 2.10 +/- 0.49 mu g h/mL and a half-life of 0.51 +/- 0.49 h (n = 3). Analysis of blood indicated only trace quantities of drug-related material in chimeric humanized and murinized FRG mice. Metabolic profiling of urine, bile and faecal extracts revealed a complex pattern of metabolites for both humanized and murinized animals with, in addition to unchanged parent drug, a variety of hydroxylated and conjugated metabolites detected. The profiles in humanized mice were different to those of both murinized and wild-type animals, e.g., a higher proportion of the dose was detected in the form of acyl glucuronide metabolites and much reduced amounts as taurine conjugates. Comparison of the metabolic profiles obtained from the present study with previously published data from C57BL/6J mice and humans revealed a greater, though not complete, match between chimeric humanized mice and humans, such that the liver humanized FRG model may represent a model for assessing the biotransformation of such compounds in humans.
机译:在10mg / kg的单口口服剂量以嵌合肝脏人源化和鼠标化FRG和C57BL / 6小鼠的单口口服剂量后,研究了双氯芬酸的药代动力学。此外,在嵌合肝脏人源化和鼠标肌肤小鼠中研究了代谢和排泄。双氯芬酸在0.25小时后达到2.43 +/-0.9μg/ ml(n = 3)的最大血液浓度,含有3.67μg/ ml的AUC(INF)和0.86小时的有效半衰期(n = 2)。在鼠静血化的动物中,用AUC(INF)为0.25小时的4.94 +/-2.93μGH/ ml和0.52 +的半衰期,最大血液浓度为0.25小时,为0.25小时剂量为3.86 +/-2.31μg/ ml / - 0.03小时(n = 3)。在C57BL / 6J小鼠中,观察2.31 +/-0.53μg/ ml的平均峰血液浓度为0.25小时,平均AUC(INF)为2.10 +/- 0.49 mu GH / ml和半衰期0.51 +/- 0.49 h(n = 3)。血液分析仅表明嵌合人源化和鼠标化小鼠中痕量的药物相关材料。尿液,胆汁和粪便提取物的代谢分析揭示了人源化和鼠主义动物的复杂代谢物模式,除了未改变的母体药物,检测到各种羟基化和共轭代谢物。人源化小鼠的曲线与鼠毒性和野生型动物的曲线不同,例如,以酰基葡萄糖醛酸代谢物的形式检测较高比例的剂量,并作为牛磺酸缀合物的量减少。从本研究中获得的来自来自C57BL / 6J小鼠和人类的先前公布的数据的代谢谱的比较揭示了更大的诸如未完成的嵌合人源化小鼠和人类之间的匹配,使得肝脏人化FRG模型可以代表评估模型这种化合物的生物转化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号